Sign in
Taking people in South KoreaPhase 2/3

Tests ACP-204 for psychosis in people with Alzheimer's disease

Tests ACP-204 against placebo in adults with Alzheimer's disease psychosis.

Key facts

Who runs it
ACADIA Pharmaceuticals Inc.
Where
Incheon and Seoul, South KoreaSee the 8 sitesAlso in 11 other countries, 147 sites
Registry title
ACP-204 in Adults With Alzheimer's Disease Psychosis
Status
Recruiting
Phase
Phase 2/3
People taking part
1,074 people, planned
Started
14 Nov 2023
Expected to end
Feb 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ACP-204
  • Placebo
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 55 to 95 with Alzheimer's disease who also have psychotic symptoms such as delusions or hallucinations. It tests the drug ACP-204 against placebo.

Age
55 to 95 years
Sex
Men and women can join.
Disease stage
Possible or probable Alzheimer's disease with psychosis lasting at least 2 months. MMSE score of 6 to 24.
Earlier treatment
People taking a cholinesterase inhibitor or memantine must be on a stable dose. Anti-tau therapy or donanemab within 2 months before screening is not allowed.
Biomarker or test result
A blood test or documented evidence (for example PET scan or spinal fluid test) showing amyloid plaque and changes consistent with Alzheimer's disease.

Main reasons for not taking part

  • Needs a medication the protocol prohibits
  • In hospice or end-of-life care, bedridden, or needs skilled nursing care
  • Psychotic symptoms mainly caused by delirium, substance abuse, or another medical or psychiatric condition
  • History of cerebral amyloid angiopathy, epilepsy, brain tumour, or unexplained fainting
  • Atrial fibrillation or symptomatic orthostatic hypotension

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Is male or female and ≥55 and ≤95 years of age living in the community or in an institutionalized setting
  • Meets clinical criteria for possible or probable AD based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria
  • Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association (IPA)
  • Has either blood-based biomarker or documented evidence (e.g. positron emission tomography, cerebrospinal fluid biomarker) indicating amyloid plaque deposition and neuropathologic change consistent with AD
  • Has a prior magnetic resonance imaging or computed tomography scan of the brain that is consistent with the diagnosis of AD
  • Meets revised criteria for psychosis in major or mild neurocognitive disorder as per International Psychogeriatrics Association
  • MMSE score ≥6 and ≤24
  • Psychotic symptoms for at least 2 months
  • Lives in a stable place of residence and there are no plans to change living arrangements
  • Has a designated study partner/caregiver
  • Able to complete all study visits with a study partner/caregiver
  • Must be on a stable dose of cholinesterase inhibitor or memantine, if applicable

Who cannot take part

  • Requires treatment with a medication prohibited by the protocol
  • Is in hospice and receiving end-of-life palliative care, or has become bedridden
  • Treatment with anti-tau therapy or donanemab within 2 months prior to Screening; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met
  • Psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition other than dementia
  • Known history of cerebral amyloid angiopathy, epilepsy, central nervous system neoplasm, or unexplained syncope
  • Protocol-defined exclusionary clinical laboratory findings
  • Requires skilled nursing care
  • Atrial fibrillation
  • Symptomatic orthostatic hypotension

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 95 years old?

Where in South Korea

Also in 11 other countries, 147 sites

  • Gachon University Gil Medical CenterIncheon, South KoreaContact: Christine MurphyTaking people
  • Inha University HospitalIncheon, South KoreaContact: Christine MurphyTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Christine MurphyTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Christine MurphyTaking people
  • SMG-SNU Boramae Medical CenterSeoul, South KoreaContact: Christine MurphyTaking people
  • Eunpyeong St. Mary's HospitalSeoul, South KoreaContact: Christine MurphyNo longer taking part
  • Hanyang University Seoul HospitalSeoul, South KoreaContact: Christine MurphyNo longer taking part
  • Konkuk University Medical CenterSeoul, South KoreaContact: Christine MurphyNo longer taking part

About the trial

What the trial wants to find out

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP

Read full original descriptionShow less

* Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1.

All 3 substudies will be analyzed independently of each other.

Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).

The 3 groups in the trial

  • ACP-204 30 mgTreatment being tested

    Administration once daily at approximately the same time of day, with or without food

    Treatment: ACP-204

  • ACP-204 60 mgTreatment being tested

    Administration once daily at approximately the same time of day, with or without food

    Treatment: ACP-204

  • PlaceboPlacebo, for comparison

    Administration once daily at approximately the same time of day, with or without food

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis
Plain-language title
Tests ACP-204 for psychosis in people with Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06159673, who can take part
Record updated
5 November 2026